Skip to content
10-Q

Quarterly Report

Zentalis Pharmaceuticals, Inc. ZNTL

0001725160-26-000042

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 71.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 70.26M sh
Shares Diluted Q1 2026 · Mar 31, 2025 71.68M sh
Capex Q1 2026 · Mar 31, 2026 $34K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$32.96M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$32.64M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $31.93M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $36M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $41.93M
Stockholders Equity Q1 2026 · Mar 31, 2026 $182.68M
Stockholders Equity Q1 2026 · Dec 31, 2025 $216.2M
Current Liabilities Q1 2026 · Mar 31, 2026 $35.24M
Current Liabilities Q1 2026 · Dec 31, 2025 $36.56M
Total Liabilities Q1 2026 · Mar 31, 2026 $70.39M
Total Liabilities Q1 2026 · Dec 31, 2025 $72.76M
Current Assets Q1 2026 · Mar 31, 2026 $218.1M
Current Assets Q1 2026 · Dec 31, 2025 $253.19M
Total Assets Q1 2026 · Mar 31, 2026 $253.07M
Total Assets Q1 2026 · Dec 31, 2025 $288.97M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.50
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.67
Eps Basic Q1 2026 · Mar 31, 2026 −$0.50
Eps Basic Q1 2026 · Mar 31, 2025 −$0.67
Sga Expense Q1 2026 · Mar 31, 2026 $9.14M
Sga Expense Q1 2026 · Mar 31, 2025 $10.58M
Rd Expense Q1 2026 · Mar 31, 2026 $28.72M
Rd Expense Q1 2026 · Mar 31, 2025 $27.25M
Net Income Q1 2026 · Mar 31, 2026 −$35.35M
Net Income Q1 2026 · Mar 31, 2025 −$48.28M
Operating Income Q1 2026 · Mar 31, 2026 −$37.86M
Operating Income Q1 2026 · Mar 31, 2025 −$45.62M